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Background: In our emergency department, we collect blood in Rapid Serum Tubes (RSTs; Becton Dickinson,
Franklin Lakes, NJ), in which clotting times are reduced. We investigated the influence of RST use on cardiac
troponin T (hs-cTnT) and creatine kinase-MB (CK-MB) test results, in comparison with the use of tubes featuring a
separator gel containing a clotting activator (SSTs; Green-vac, Yongin, Korea).
Methods: Samples from 60 patients were divided into equal aliquots and placed into RSTs and SSTs; hs-cTnT and
CK-MB concentrations were determined using an autoanalyzer (Elecsys 2010) running commercial assays (Roche
Diagnostics, Penzberg, Germany). Between-tube differences in CK-MB and hs-cTnT values were compared using the
paired t-test, and correlations among variables were evaluated by calculation of Spearman correlation coefficients
(r values). Deming regression analysis was performed and Bland-Altman plots were constructed.
Results: The hs-cTnT and CK-MB test results obtained from samples placed into RSTs and SSTs did not differ
(p > 0.1). The correlations between the concentrations of hs-cTnT and CK-MB in samples placed into RSTs and SSTs
were good; both r values were unity (p < 0.001). Deming regression analysis yielded the equation: RST [hs-cTnT] =
0.98 SST [hs-cTnT] + 0.69 pg/ml; and RST [CK-MB] = 0.95 SST [CK-MB]–0.09 ng/ml. The biases of 1.4 pg/ml (95% CI:
minus 8.1–10.7 pg/ml) for hs-cTnT levels and 0.249 ng/ml (95% CI: minus 0.682–1.681 ng/ml) for CK-MB levels
assayed using either tube was acceptable.
Conclusion: The hs-cTnT and CK-MB test results did not significantly differ when either tube was used. RST tube
use was associated with a short clotting time; this was an advantage in an emergency laboratory setting.
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Assay of total creatine kinase (total CK), CK-MB, myo-
globin, and troponins are conducted on the sera of pa-
tients with suspected acute myocardial infarction (AMI)
[1]. Cardiac troponins (cTn) are structural proteins uni-
que to the heart. Detection of cTn in peripheral blood
indicates cardiomyocyte necrosis [1]. A very sensitive
assay for high-sensitivity cardiac troponin T (hs-cTnT)
was recently developed, enabling measurements of con-
centrations 10-fold lower than previously. Use of this as-
say in patients with suspected acute coronary syndromes* Correspondence: yaseminbudak2000@yahoo.com
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reproduction in any medium, provided the orhas improved the accuracy of MI diagnosis compared with
the standard cTnT assay [2-5]. In an emergency depart-
ment, it is important that the concentrations of cardiac
markers be determined rapidly after sample-taking; hence
short “turnaround times” (TATs) are required. Exis-
ting guidelines recommend that cardiac biomarker
TATs should be < 60 min [6].
Rapid technological advances (yielding “Stat” tests)
have dramatically improved the TAT. Stat tests are opti-
mal when preanalytical delay is also reduced. Thus, pre-
analytical processes should be carefully planned and
workup time minimized.
Blood specimens collected in plasma tubes do not clot
prior to centrifugation. This allows blood to be drawn,
mixed, and immediately centrifuged, yielding rapid testtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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than in plasma [7,8], and differences between plasma
and serum test results have often been documented [9].
Recently, Gerhardt et al. [10] and Stiegler et al. [11]
showed that the levels of cardiac troponin T (cTnT)
were 15% lower in heparinized plasma than in serum.
Stiegler [11] suggested that the difference could be
explained by conformational changes of the antigen in-
duced by direct interactions between the positively
charged (pI 5.1) cTnT molecule and negatively charged
heparin. Such complexes can interfere with antibody-
antigen interaction, as shown previously by Katrukha
et al. [12]. On the basis of these results, Roche Diagnos-
tics, manufacturer of the cTnT assay, have advised cus-
tomers not to use heparinized plasma for assay of cTnT
(3rd generation Elecsys® TnT assay).
Over the past few years we have used SSTs for blood
collection, as the tubes facilitate rapid separation of
serum from cells [13]. SSTs contain a gel barrier that
moves to the serum/clot interface during centrifuga-
tion [13]. The RST is a recently released serum sepa-
rator tube containing thrombin as a clotting activator,
affording rapid serum separation and short test TATs [14],
both of which are invaluable in emergency situations.
If a switch to use of RST tubes is contemplated to
reduce TATs, it is important to compare test values
obtained using different tubes. We assessed the com-
parability of hs-cTnT (Roche Diagnostics, Germany;
lot161334) and CK-MB (Roche Diagnostics, Germany;
lot161515) test results from patients whom we suspected
had experienced acute myocardial infarction (AMI) using
the new RST tubes (BD, Franklin Lakes NJ; lot 110408)
and previously employed SSTs (Green-vac, Yongin, Korea;
lot 110218) for specimen collection. Data were obtained
using a Roche Diagnostics Elecsys 2010 analyzer (Roche
Diagnostics, Penzberg, Germany) running commercially
available assays.
Methods
This study was approved by Sevket Yilmaz Research and
Education Hospital Ethics Committee. The study was
conducted over a period of 10 days and included data
from 60 patients.
Patients admitted to our emergency department with a
chief complaint of chest pain and with a request for CK-
MB and hs-cTnT analysis, regardless of age or gender,
were included. Blood samples were drawn by trained
technologists and collected into RST and SST collection
tubes in random order, with the tubes filled to capacity.
In line with the manufacturers’ instructions, RSTs were
inverted 5–6 times and centrifuged (1600 × g, 10 min)
after 5 min whereas SSTs were inverted 5–6 times and
centrifuged after 30 min (1600 × g, 10 min). Serum CK-
MB (mass) and hs-cTnT concentrations were measuredusing commercially available electrochemiluminescence
immunoassays on an Elecsys 2010 analyzer (Roche Diag-
nostics GmbH, Mannheim, Germany), with each sample
tested in duplicate.
Prior to specimen analysis, we ran a two-level quality-
control (QC) test using materials supplied by the tube
manufacturers (PCTN1 lot 164408 and PCTN2 lot
163162). Between-day differences in QC sample results
were determined after analysis, in duplicate, on each of
20 days, using a single reagent batch and a single cali-
bration curve. Within-day precision was calculated by
running 20 replicates simultaneously.Statistical analysis
Data were evaluated using SPSS version 13.0 (SPSS Inc.,
Chicago, IL) and Analyse-It version 2.04 (Analyse-It
Software, Leeds, UK). Descriptive statistical values (arith-
metical and geometric means, with SDs) were calculated
in a conventional manner. Differences between CK-MB
and hs-cTnT values of samples obtained from RSTs and
SSTs were compared using the paired t-test. Correlations
were determined via calculation of Spearman correlation
coefficients (r values). For all statistical comparisons, p
values less than 0.05 were considered significant. Data
concordance was evaluated via Deming regression ana-
lysis. The mean of differences (bias) and limits of ag-
reement were calculated using the Bland and Altman
method [15].Results
For quality assurance purposes, our laboratory partici-
pates in an external quality assessment scheme run by
Labquality, Helsinki, Finland. At the time of the present
study, the QC program reported average values obtained
in 107 participating laboratories. For CK-MB, the mean
was 4.6 μg/l and our value was 4.7 μg/l; for CK-MB, the
mean was 2.7 μg/l and our value was 2.9 μg/l; for hs-
TNT, the mean was 882.7 ng/l and our value was
952.7 ng/l; and for hs-TNT the mean was 1,337 ng/l and
our value was 1,348.7 ng/l. All of our data were within ±2
SDs of the mean values.
Intra- and inter-day variabilities were determined by
multiple assays of QC samples, within day and between
day CVs were < 6% for both assays. For QC1, the mean
CK-MB was 6.2 μg/l and the mean hs-cTNT was 28 ng/l;
for QC2, the means were 49.6 μg/l and 156 ng/l,
respectively.
The hs-cTnT values of samples analyzed in the present
study ranged from 3–712 pg/ml and the CK-MB values
from 1.03–75.83 ng/ml. The mean CK-MB level ob-
tained using RSTs was 6.56 ± 13.12 ng/ml whereas that
for SST samples was 6.81 ± 13.58 ng/ml (paired t-test:
0.002). The mean hs-cTnT value obtained using SST
Figure 1 Deming fit (solid black line) with 95% confidence intervals for the SST hs-cTnT results vs RST results. Concentrations are
expressed as picograms per milliliter.
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into RSTs 73.5 ± 7.9 pg/ml.
The Spearman correlation coefficients were r = 1.0
(p < 0.001) when hs-cTnT and CK-MB assay data were
compared. The correlations between hs-cTnT and CK-
MB serum concentrations measured using RSTs and
SSTs were very strong (r = 1.0 for both) (p < 0.001)
(Figures 1 and 2). The bias values were 1.4 pg/mlFigure 2 Deming fit (solid black line) with 95% confidence intervals f
expressed as nanograms per milliliter.(95% CI: minus 8.1–10.7 pg/ml) when the hs-cTnT
values yielded upon use of either tube type were com-
pared (Figure 3), and 0.249 ng/ml (95% CI: minus
0.682–1.681 ng/ml) for CK-MB (Figure 4). Deming re-
gression analysis of hs-cTnT measurements obtained
using either assay, on samples from all 60 patients
(Figure 1), yielded the following data: slope, 0.98 [95%
confidence interval (95% CI), 0.97–0.98]; and interceptor the SST CK-MB results vs RST results. Concentrations are
Figure 3 Bland-Altman plot of SST and RST tube hs-cTnT results showing the 95% limits of agreement.
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hs-cTnT value was 0.98 × (the SST hs-cTnT value) +
0.69 pg/ml. Deming regression analysis of CK-MB levels
yielded the following data: slope, 0.95 (95% CI, 0.90–
1.00); and intercept, minus 0.09 ng/ml (95% CI, minus
0.51–0.32 ng/ml).
Discussion
In the present study, we compared data from samples
collected from patients undergoing clinical testing for
suspected or confirmed MI, rather than those from sam-
ples obtained from healthy volunteers in a non-emergencyFigure 4 Bland-Altman plot of SST and RST tube CK-MB results showienvironment. We found that the Spearman correlation co-
efficient was unity, indicating a perfect correlation, when
hs-cTnT and CK-MB test results on samples collected into
RSTs and SSTs were compared.
Clotting should continue for 30 min to ensure com-
plete clot formation with SST tubes [10]. If a tube is
centrifuged too soon, gelatinous and/or fibrin-containing
serum samples will be obtained; these will clog the
analyzer probes. Roberts et al. [16] observed that incom-
pletely clotted specimen contributed to the false elevations
in cardiac TnI concentrations with the Stratus II batch
analyzer (Dade International). In emergency laboratories,ng the 95% limits of agreement.
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occur in 5 min if blood sample tubes contain thrombin
[14], the RSTs used in the present study are such tubes.
We have shown herein that simultaneous quantification
of CK-MB and hs-cTnT in samples derived from RSTs
and SSTs yielded similar results.
In our present work, Deming regression analysis yiel-
ded the appropriate y-intercept value of zero for both
tests but the slope of the regression line did not approxi-
mate unity, suggesting that, in addition to the presence
of a small constant bias, a small (and nonsignificant)
proportional difference existed between the test results
obtained upon use of the two tube types [17].
The acceptable degree of imprecision of both the CK-
MB and hs-cTnT assays is < 10% at the 99th percentile
reference level [18]. In our hands, the imprecision levels
of either assay were below this value. Notably, participa-
tion of our laboratory in internal and external quality as-
surance programs, and use of an automated analyzer,
indicate that RST tubes may be used to reduce TAT.
The quality of assay data is high. Importantly, many re-
ports have shown that serum, rather than heparinized
plasma, should be used for cardiac marker determina-
tion [10,11]. In a recent study, Strathmann et al. [19]
showed that specimens collected into RSTs yielded
fewer false-positive immunoassay results than did those
collected as heparinized plasma samples when the
Beckman Coulter Unicel DxI instrument was used to eval-
uate the levels of troponin I and the creatine kinase-MB
isozyme.
The US CLIA 1988 rules indicate that differences of
7.8% in CK-MB levels, and 23% in cTnT levels, around
target values, are acceptable [20] because of biological
variation. In the present study, we observed that the
hs-cTnT concentrations of serum samples collected into
SSTs were slightly higher than were those of samples
collected into RSTs. We also found that the serum CK-
MB concentrations of samples collected into SSTs were
somewhat higher than were those of samples collected
into RSTs, but no detected difference was clinically sig-
nificant. The bias values were smaller than are the US
CLIA 1988 targets. The bias may be attributable to the
fact that samples taken into SSTs have a longer clotting
time; RST samples are analyzed about 30 min earlier
than are SST samples. Also, the two tube types employ
different clotting agents.
An increase of >2.0 ng/ml in CK-MB level compared
to baseline concentrations is indicative of myocardial
damage in patients without AMI. For both tube types,
the CK-MB assay bias was 0.249 ng/ml, with zero in-
cluded in the 95% confidence intervals. Such biases are
acceptable [21], although additional data are needed to
support the hypothesis that results from SST and RST
are clinically interchangeable.Heparin is utilized clinically to inhibit clotting in crit-
ical care patients. Blood samples from patients adminis-
tered heparin prior to blood collection can contain
excess concentrations of heparin, increasing clotting
time in the collection tube and thereby increasing the
potential for the formation of “latent” fibrin in the
preanalytical phase. Although few of the samples in this
study were from patients receiving heparin therapy, the
inclusion of this subgroup may have confounded our re-
sults and constitutes a limitation of this study. Add-
itional studies are needed to assess the influence of
heparin therapy on CK-MB and hs-cTnT concentrations
measured in RST and SST tubes.
Preanalytical variables associated with blood collection
should be further standardized to ensure the accuracy of
test results. It is impractical to expect tube manufac-
turers to test their tubes on all possible assay platforms;
this is a task for individual laboratories.
Conclusions
We conclude that RSTs are suitable for sample collec-
tion prior to CK-MB and hs-cTnT analysis in a hospital
emergency laboratory. RST use is associated with a short
clotting time, which is valuable in an emergency setting.
Additionally, the tubes are inexpensive.
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